Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Targeted therapies: pazopanib for soft-tissue sarcoma: a PALETTE of data emerges.

Ray-Coquard I, Thomas D.

Nat Rev Clin Oncol. 2012 Jul 3;9(8):431-2. doi: 10.1038/nrclinonc.2012.113. No abstract available.

PMID:
22751280
2.

Differences in the responses to pazopanib and the prognoses of soft tissue sarcomas by their histological eligibility for the PALETTE study.

Nakano K, Motoi N, Inagaki L, Tomomatsu J, Gokita T, Ae K, Tanizawa T, Shimoji T, Matsumoto S, Takahashi S.

Jpn J Clin Oncol. 2015 May;45(5):449-55. doi: 10.1093/jjco/hyv022. Epub 2015 Feb 26.

3.

Pazopanib in sarcomas: expanding the PALETTE.

Wilky BA, Meyer CF, Trent JC.

Curr Opin Oncol. 2013 Jul;25(4):373-8. doi: 10.1097/CCO.0b013e3283622d3a. Review.

4.

Pazopanib in the treatment of soft tissue sarcoma.

Schöffski P.

Expert Rev Anticancer Ther. 2012 Jun;12(6):711-23. doi: 10.1586/era.12.41. Review.

PMID:
22716487
5.

Pazopanib: in advanced soft tissue sarcoma.

Deeks ED.

Drugs. 2012 Nov 12;72(16):2129-40. doi: 10.2165/11209950-000000000-00000.

PMID:
23072642
6.

Pazopanib, a new therapy for metastatic soft tissue sarcoma.

Verweij J, Sleijfer S.

Expert Opin Pharmacother. 2013 May;14(7):929-35. doi: 10.1517/14656566.2013.780030. Epub 2013 Mar 14. Review.

PMID:
23488774
7.

Long-term responders and survivors on pazopanib for advanced soft tissue sarcomas: subanalysis of two European Organisation for Research and Treatment of Cancer (EORTC) clinical trials 62043 and 62072.

Kasper B, Sleijfer S, Litière S, Marreaud S, Verweij J, Hodge RA, Bauer S, Kerst JM, van der Graaf WT.

Ann Oncol. 2014 Mar;25(3):719-24. doi: 10.1093/annonc/mdt586. Epub 2014 Feb 6.

8.

Clinical trial end points for assessing efficacy of novel therapies for soft-tissue sarcomas.

Chmielowski B, Federman N, Tap WD.

Expert Rev Anticancer Ther. 2012 Sep;12(9):1217-28. doi: 10.1586/era.12.100. Review.

PMID:
23098121
9.

Cost-effectiveness analysis of pazopanib in second-line treatment of advanced soft tissue sarcoma in Spain.

Villa G, Hernández-Pastor LJ, Guix M, Lavernia J, Cuesta M.

Clin Transl Oncol. 2015 Jan;17(1):24-33. doi: 10.1007/s12094-014-1191-9. Epub 2014 Jul 1.

PMID:
24981588
10.

Hypertension (HTN) as a potential biomarker of efficacy in pazopanib-treated patients with advanced non-adipocytic soft tissue sarcoma. A retrospective study based on European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 trials.

Duffaud F, Sleijfer S, Litière S, Ray-Coquard I, Le Cesne A, Papai Z, Judson I, Schöffski P, Chawla SP, Dewji R, Marreaud S, Verweij J, van der Graaf WT.

Eur J Cancer. 2015 Nov;51(17):2615-23. doi: 10.1016/j.ejca.2015.08.002. Epub 2015 Aug 25.

PMID:
26321011
11.

Pazopanib and the treatment palette for soft-tissue sarcoma.

Bramwell VH.

Lancet. 2012 May 19;379(9829):1854-6. doi: 10.1016/S0140-6736(12)60739-9. Epub 2012 May 16. No abstract available.

PMID:
22595798
12.

Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043).

Sleijfer S, Ray-Coquard I, Papai Z, Le Cesne A, Scurr M, Schöffski P, Collin F, Pandite L, Marreaud S, De Brauwer A, van Glabbeke M, Verweij J, Blay JY.

J Clin Oncol. 2009 Jul 1;27(19):3126-32. doi: 10.1200/JCO.2008.21.3223. Epub 2009 May 18.

13.

Pazopanib: a promising new agent in the treatment of soft tissue sarcomas.

Kasper B, Hohenberger P.

Future Oncol. 2011 Dec;7(12):1373-83. doi: 10.2217/fon.11.116.

PMID:
22112314
14.

Nursing considerations with pazopanib therapy: focus on metastatic renal cell carcinoma.

Bourdeanu L, Twardowski P, Pal SK.

Clin J Oncol Nurs. 2011 Oct;15(5):513-7. doi: 10.1188/11.CJON.513-517.

PMID:
21951737
15.

Pazopanib: the newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma.

Keisner SV, Shah SR.

Drugs. 2011 Mar 5;71(4):443-54. doi: 10.2165/11588960-000000000-00000. Review.

PMID:
21395357
16.

[Pharmacological profile and clinical results in advanced soft tissue sarcoma patients of pazopanib hydrochloride (Votrient(®))].

Arai H, Fukasawa N, Ueta F.

Nihon Yakurigaku Zasshi. 2013 Jan;141(1):37-42. Review. Japanese. No abstract available.

PMID:
23302947
17.

Pazopanib a tyrosine kinase inhibitor with strong anti-angiogenetic activity: a new treatment for metastatic soft tissue sarcoma.

Ranieri G, Mammì M, Donato Di Paola E, Russo E, Gallelli L, Citraro R, Gadaleta CD, Marech I, Ammendola M, De Sarro G.

Crit Rev Oncol Hematol. 2014 Feb;89(2):322-9. doi: 10.1016/j.critrevonc.2013.08.012. Epub 2013 Sep 4. Review.

PMID:
24041629
18.

Pazopanib for metastatic soft-tissue sarcoma.

Endo M, Nielsen TO.

Lancet. 2012 Sep 1;380(9844):801; author reply 801. doi: 10.1016/S0140-6736(12)61440-8. No abstract available.

PMID:
22939674
19.

Patient Education Needs With Pazopanib Therapy for Soft Tissue Sarcoma.

Becze E.

ONS Connect. 2016 Mar;31(3):18-9. No abstract available.

PMID:
27044202
20.

Patient-reported outcomes enhance understanding of the impact of pazopanib in soft tissue sarcoma.

Gotay C.

Cancer. 2015 Sep 1;121(17):2868-70. doi: 10.1002/cncr.29429. Epub 2015 May 29. No abstract available.

PMID:
26033391
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk